» Articles » PMID: 12676944

Protein Kinase C Nu/protein Kinase D3 Nuclear Localization, Catalytic Activation, and Intracellular Redistribution in Response to G Protein-coupled Receptor Agonists

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Apr 5
PMID 12676944
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The protein kinase D (PKD) family consists of three serine/threonine kinases: PKC micro/PKD, PKD2, and PKCnu/PKD3. Whereas PKD has been the focus of most studies, virtually nothing is known about the effect of G protein-coupled receptor agonists (GPCR) on the regulatory properties and intracellular distribution of PKD3. Consequently, we examined the mechanism that mediates its activation and intracellular distribution. GPCR agonists induced a rapid activation of PKD3 by a protein kinase C (PKC)-dependent pathway that leads to the phosphorylation of the activation loop of PKD3. Comparison of the steady-state distribution of endogenous or tagged PKD3 versus PKD and PKD2 in unstimulated cells indicated that whereas PKD and PKD2 are predominantly cytoplasmic, PKD3 is present both in the nucleus and cytoplasm. This distribution of PKD3 results from its continuous shuttling between both compartments by a mechanism that requires a nuclear import receptor and a competent CRM1-nuclear export pathway. Cell stimulation with the GPCR agonist neurotensin induced a rapid and reversible plasma membrane translocation of PKD3 that is PKC-dependent. Interestingly, the nuclear accumulation of PKD3 can be dramatically enhanced in response to its activation. Thus, this study demonstrates that the intracellular distribution of PKD isoenzymes are distinct, and suggests that their signaling properties are regulated by differential localization.

Citing Articles

Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer.

Sun X, Teper Y, Sinnet-Smith J, Sinnett-Smith J, Markarian M, Hines O Mol Cancer Res. 2024; 23(3):236-249.

PMID: 39642318 PMC: 11875952. DOI: 10.1158/1541-7786.MCR-24-0785.


Protein kinase D1 - A targetable mediator of pancreatic cancer development.

Fleming Martinez A, Storz P Biochim Biophys Acta Mol Cell Res. 2023; 1871(2):119646.

PMID: 38061566 PMC: 10872883. DOI: 10.1016/j.bbamcr.2023.119646.


Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.

Kozaki R, Yasuhiro T, Kato H, Murai J, Hotta S, Ariza Y PLoS One. 2023; 18(3):e0282166.

PMID: 36897912 PMC: 10004634. DOI: 10.1371/journal.pone.0282166.


Potential role for protein kinase D inhibitors in prostate cancer.

Chalfant V, Riveros C, Singh P, Shukla S, Balaji N, Balaji K J Mol Med (Berl). 2023; 101(4):341-349.

PMID: 36843036 DOI: 10.1007/s00109-023-02298-4.


Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth of murine enteroids.

Sinnett-Smith J, Torres-Marquez M, Chang J, Shimizu Y, Hao F, Martin M Am J Physiol Cell Physiol. 2023; 324(4):C807-C820.

PMID: 36779664 PMC: 10042602. DOI: 10.1152/ajpcell.00286.2022.